<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04065893</url>
  </required_header>
  <id_info>
    <org_study_id>CRT-Bivent.</org_study_id>
    <nct_id>NCT04065893</nct_id>
  </id_info>
  <brief_title>Impact of Catheter Ablation of Ventricular Arrhythmias on Suboptimal Biventricular Pacing in Cardiac Resynchronization Therapy</brief_title>
  <official_title>Impact of Catheter Ablation of Ventricular Arrhythmias on Suboptimal Biventricular Pacing in Cardiac Resynchronization Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Köln</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Köln</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac resynchronization therapy reduces mortality in patients with systolic heart failure
      and left bundle branch block. Reduced biventricular pacing can lead to therapy failure. Most
      effective mortality reduction was seen with a BiV pacing above 98%.

      Reduced BiV pacing is a common phenomenon with potential impact on CRT-response and pts'
      prognosis. Frequent ventricular ectopy may be associated with attenuated benefit from CRT.
      The investigators sought to systematically assess the effect of ventricular arrhythmia
      treatment on BiV pacing.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Biventricular pacing</measure>
    <time_frame>3 month after intervention biventricular pacing (%) is routinely monitored</time_frame>
    <description>Influence of intervention (Ablation/medical treatment) on previously reduced biventricular pacing percentage (&lt;98%). Biventricular pacing is measured in percentage of stimulation and is monitored at routine device interrogation.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Systolic Heart Failure</condition>
  <condition>Ventricular Premature Complexes</condition>
  <condition>Ventricular Tachycardia</condition>
  <condition>Cardiac Resynchronization Therapy</condition>
  <condition>Reduced Biventricular Pacing</condition>
  <arm_group>
    <arm_group_label>Catheter ablation group</arm_group_label>
    <description>Patients with reduced biventricular pacing due to PVC or VT receiving catheter ablation of PVC/VT according to guidelines and clinical practices</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical treatment group</arm_group_label>
    <description>Patients with reduced biventricular pacing due to PVC or VT receiving intensified medical therapy (antiarrhythmics/betablocker) according to guidelines and clinical practices</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter ablation of ventricular arrhythmia</intervention_name>
    <description>PVC or VT ablation</description>
    <arm_group_label>Catheter ablation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensified medical therapy</intervention_name>
    <description>Dosage increase / new onset of Betablocker / medical antiarrhythmic medication according to guideline and clinical practice</description>
    <arm_group_label>Medical treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pts. with systolic heart failure, wide QRS complex and CRT with reduced biventricular
        pacing due to ventricular arrhythmia (PVC/VT)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  reduced biventricular pacing &lt;98% due to ventricular arrhythmia

        Exclusion Criteria:

          -  reduced biventricular pacing &lt;98% due to other cause

          -  age &lt;18

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Jakob Lüker, MD</last_name>
    <phone>+4922147832396</phone>
    <email>jakob.lueker@uk-koeln.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan-Hendrik van den Bruck, MD</last_name>
    <phone>+4922147884895</phone>
    <email>jan-hendrik.van-den-bruck@uk-koeln.de</email>
  </overall_contact_backup>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

